comparemela.com

Latest Breaking News On - Bsrela - Page 1 : comparemela.com

Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript

Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript February 22, 2024 Ardelyx, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.09. Ardelyx, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Ardelyx Fourth […]

Fosun-pharma
Laura-williams
Mike-raab
Justin-renz
Fastest-growing-industries
Growing-industries
Susan-rodriguez
Ardelyx
Nc
Fourth-quarter
Laura-williams
Bsrela

Ardelyx, Inc. (NASDAQ:ARDX) Q2 2023 Earnings Call Transcript

Ardelyx, Inc. (NASDAQ:ARDX) Q2 2023 Earnings Call Transcript August 2, 2023 Ardelyx, Inc. misses on earnings expectations. Reported EPS is $-0.19 EPS, expectations were $0.12. Operator: Hello and welcome to the Ardelyx Second Quarter 2023 Conference Call. All participants will be in listen-only mode. [Operator Instructions]. Please note this event is being recorded. I would […]

Japan
China
Japanese
Pressmaster-shutterstock
Mike-raab
Olson-pharma
Justin-renz
Kyowa-kirin-co
Kyowa-kirin
Popular-whiskey-brands
Biggest-upside-potential-according
Susan-rodriguez

Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

IBSRELA provides meaningful reduction of multiple abdominal symptoms Patient-reported outcomes are strongly correlated with IBS-C abdominal symptom score WALTHAM, Mass., May 09, 2023 Ardelyx,. | May 9, 2023

United-states
Illinois
Chicago
Canada
China
Waltham
Japan
Fosun-pharma
Briane-lacy
Twitter
Nasdaq
Linkedin

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.